Treatment and assessment
esophageal squamous cell carcinoma, tumor, death, Tumor
ADVERSE EVENT, OESOPHAGEAL SQUAMOUS CELL CARCINOMA, TUMOR, TUMOR, ADVERSE EVENT
After screening, patients with esophageal squamous cell carcinoma who met the inclusion and exclusion criteria signed the informed consent form(ICF) and then received radiotherapy at all recurrent sites, with a dose of 1.8 Gray (Gy) in 25–28 and a total radiation dose of 45–50.4 Gy. On the first day of radiotherapy, one cycle of raltitrexed (3 mg/mAt the time of enrollment, all patients provided their past medical history, imaging data, complete and continuous physical examination, functional status score, blood routine, blood biochemistry, serum tumor markers, thyroid function, electrocardiogram, pulmonary function, and other general examination items. Patients should be examined by contrast-enhanced CT and a barium meal within 1 week before radiotherapy and 4 weeks after radiotherapy. The efficacy was evaluated according to RECIST v1.1. Endoscopic ultrasonography can be performed if necessary. From the maintenance treatment phase, blood routine and blood biochemistry were tested at least every 3 weeks. Tumor markers were tested at least every 4 weeks, with enhanced CT and a barium meal every 8 weeks.Adverse events were collected and monitored from the end of chemoradiotherapy until 3 months after the last immunotherapy or death. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 5.0. After treatment, patients should return to the hospital every 8–12 weeks for a follow-up, including symptoms, physical examination, hematological evaluation, and imaging evaluation. Patients were followed up by telephone every 4–8 weeks until death or until the end of the study.